乐观
$186.19
情景价格
$121.270
+1.649 (+1.36%)收盘时
iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.
iRhythm Technologies Inc (IRTC) is a good buy right now, trading at $121.27 with a significant upside potential. The company has shown a 24% annual revenue growth over the last two years and a gross margin of 72.80% in Q2 2026, indicating strong operational efficiency. However, a key risk is the high forward P/E ratio of 90.91, which suggests that the stock is priced for high growth, and any failure to meet growth expectations could lead to a decline in share price.
Wells Fargo
$150
2026-10-06
Wells Fargo
2026-10-06
目标价
$150
Truist
$168
2026-08-10
Truist
2026-08-10
目标价
$168
Canaccord
$196
2026-08-07
Canaccord
2026-08-07
目标价
$196
Baird
$165
2026-08-07
Baird
2026-08-07
目标价
$165
Stephens
$160
2026-07-22
Stephens
2026-07-22
目标价
$160
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Wall Street's Latest Ratings Overview

Investigation into iRhythm Shareholder Rights

Three Small-Cap Stocks for Long-Term Investors

Investigation into iRhythm Shareholder Rights

iRhythm (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
iRhythm Technologies Inc (IRTC) is a good buy right now, trading at $121.27 with a significant upside potential. The company has shown a 24% annual revenue growth over the last two years and a gross margin of 72.80% in Q2 2026, indicating strong operational efficiency. However, a key risk is the high forward P/E ratio of 90.91, which suggests that the stock is priced for high growth, and any failure to meet growth expectations could lead to a decline in share price.
4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。